Jun Ma, Ting Liu, Jie Jin, Jianda Hu, Qifa Liu, Jianxiang Wang, Zhixiang Shen, Xin Du, Bin Jiang, Xianhua Meng
{"title":"中国成人复发/难治性费城阴性急性淋巴细胞白血病的观察性研究","authors":"Jun Ma, Ting Liu, Jie Jin, Jianda Hu, Qifa Liu, Jianxiang Wang, Zhixiang Shen, Xin Du, Bin Jiang, Xianhua Meng","doi":"10.2217/ijh-2018-0006","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.</p><p><strong>Patients & methods: </strong>We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.</p><p><strong>Results: </strong>Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).</p><p><strong>Conclusion: </strong>This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"7 2","pages":"IJH06"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2018-0006","citationCount":"3","resultStr":"{\"title\":\"An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia.\",\"authors\":\"Jun Ma, Ting Liu, Jie Jin, Jianda Hu, Qifa Liu, Jianxiang Wang, Zhixiang Shen, Xin Du, Bin Jiang, Xianhua Meng\",\"doi\":\"10.2217/ijh-2018-0006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.</p><p><strong>Patients & methods: </strong>We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.</p><p><strong>Results: </strong>Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).</p><p><strong>Conclusion: </strong>This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.</p>\",\"PeriodicalId\":14166,\"journal\":{\"name\":\"International Journal of Hematologic Oncology\",\"volume\":\"7 2\",\"pages\":\"IJH06\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/ijh-2018-0006\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematologic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/ijh-2018-0006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2018-0006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia.
Aim: Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.
Patients & methods: We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.
Results: Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).
Conclusion: This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.
期刊介绍：
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
